
OUT NOW A High Throughput and Low Waste Viability Assay for Microbes by @meyerct6 @danastamo nature.com/articles/s41564-0…


OUT NOW A High Throughput and Low Waste Viability Assay for Microbes by @meyerct6 @danastamo nature.com/articles/s41564-0…

Next up at #MPDD is @meyerct6 discussing MuSyC They have a webapp musyc.lolab.xyz

Pleased to share our preprint on bacterial zombies! These zombie cells are non-viable but they reshape the antibiotic tolerance of other species via paracrine secretions. Great working with @kralj_lab alumni @BruniGN and Ben. @BioFrontiers @CUBoulder biorxiv.org/content/10.1101/…

Thanks for the shout out!
This tweet is unavailable

.@meyerct6 @quarantalab @ceelox4 @AlexLubbock present #MuSyC, a consensus synergy metric for characterizing combinatorial drug interactions. #MuSyC overcomes several caveats associated with popular synergy metrics. go.nature.com/2VxQTNE

Woo! Finally. Check out our paper: MuSyC is a consensus framework that unifies multi-drug synergy metrics for combinatorial drug discovery, w/ @quarantalab #NSFfunded #NIHfunded #whatweneedmoreofistheory rdcu.be/cqKIo

Happy to share our paper online today at Cytometry A describing DebarcodeR - an algorithm for demultiplexing fluorescence cell barcoded (FCB) flow cytometry data. (1/12) @jonathanirish @BrianOBachmann onlinelibrary.wiley.com/doi/…

Great example of the impact of undergraduate research @CUBoulder. Congrats Eugene Miller @eugenejoemiller for getting published as an undergraduate!

New work from @BioFrontiers on machine learning applied to detecting antibiotic sensitivity. Thanks to Joel Kralj, Megan Jewel, and @eugenejomiller! Machine Learning Establishes Single-Cell Calcium Dynamics as an Early Indicator of Antibiotic Response mdpi.com/1098518

A Bayesian framework for intelligently deploying universal COVID testing: disq.us/t/3wgezdl Related to the recent, fantastic article by @TomChivers in @guardian theguardian.com/world/2021/a…

This week in the field of mathematical oncology: issue 105. <glioblastoma models, drug synergistic effects, the cancer microbiome, organoid dynamics> buff.ly/3atSpCC

Really nice overview by the @quarantalab on assumptions on biology and data made by different #DrugSynergy models. This is critical when choosing the right synergy model for your data! sciencedirect.com/science/ar…

Carlos Lopez & Vito Quaranta tackle issues impacting all aspects of combination therapy discovery and deployment in this CellPress review article titled "Charting the Fragmented Landscape of Drug Synergy" https://t.co/ToJ5jUgBfG @CellPressNews @quarantalab @ceelox4 @meyerct6

I am pleased to share our in-depth review on drug synergy is now available from @TrendsinPharma. Special thanks to @quarantalab and @ceelox4 for their contributions and @NSFGRF and @NCIsysbio which fund this work. #NSFfunded #drugsynergy sciencedirect.com/science/ar…

A great example of motivating experimental design from models. And an innovative approach to understanding the molecular mechanisms under-girding "synergy." Such studies help point toward a future of rational design and deployment of personalized combination therapy.

Great new work from the @FertigLab on a novel approach to identifying combination therapy in hepatocellular carcinoma! nature.com/articles/s41540-0… They use a mathematical model of the HGF/Met pathway to investigate combination strategies. @quarantalab @HopkinsMedicine